Black Diamond Therapeutics, Inc. (BDTX)

Black Diamond Therapeutics' stock has experienced a downtrend of 23.14% in the past six months as of May 26, 2022, but as of May 6, 2026, the share price increased by 81.94% from May 7, 2025. The company reported a net loss of $9.0 million in Q1 2026, compared to a net income of $56.5 million in Q1 2025, which included a $70.0 million upfront license payment from Servier, and ended Q1 2026 with $118.3 million in cash, expected to fund operations into the second half of 2028. Silevertinib Phase 2 data was presented at the 2026 ASCO Annual Meeting. Analysts have a consensus rating of "Strong Buy" with a median price target of $10.77 as of May 8, 2026. Technical signals have been mixed, with some bullish and bearish indicators.

As a clinical-stage oncology company, Black Diamond Therapeutics does not experience demand seasonality in the traditional sense. Its revenue and valuation are primarily driven by its research and development pipeline and clinical trial readouts, rather than seasonal fluctuations in product sales. The broader oncology market faces ongoing pressures from policy uncertainty, reimbursement constraints, and workforce shortages, which are not typically seasonal.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on developing MasterKey therapies for genetically defined tumors. The company develops small-molecule inhibitors targeting genetic mutations across various tumor types. Its major product candidates include Silevertinib, a brain-penetrant EGFR MasterKey inhibitor in Phase 2 clinical trials; BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors, which has been out-licensed to Servier; and BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations in the preclinical stage.

Black Diamond Therapeutics is headquartered in Cambridge, Massachusetts, and has a subsidiary, Black Diamond Therapeutics (Canada) Inc.

Black Diamond Therapeutics maintains a positive reputation due to promising clinical trial results and a solid financial outlook. Analysts have a "Strong Buy" consensus rating for the stock. Earnings reports have generally been received positively, and the efficacy of silevertinib in EGFR-mutant NSCLC has contributed to this positive sentiment. There have been no specific events in the past year that have significantly negatively impacted the company's brand reputation.

Black Diamond Therapeutics has a diverse ownership structure, with institutional shareholders holding approximately 65.99% of the stock, insiders owning about 35.25%, and retail investors holding 0.00%. Major institutional owners include T. Rowe Price Investment Management, Inc., NEA Management Company, LLC, Vanguard Group Inc, Acadian Asset Management Llc, Marshall Wace, Llp and BlackRock, Inc. The largest individual shareholder is Ali Behbahani, owning 8.99 million shares, representing 15.69% of the company.